FindMyRecallSubscribe
Class I: serious health riskOngoing

Exela Pharma Sciences Midazolam in 0 Recall

Midazolam in 0

Exela Pharma Sciences LLC · Lenoir, NC

Risk level
Class I
Reported by FDA
Nov 29, 2023
Recall ID
D-0117-2024
Check your lot numberHow we source this data

Summary

Exela Pharma Sciences recalled Midazolam in 0 starting Oct 18, 2023. The FDA classified it as Class I (serious health risk) and published enforcement report D-0117-2024 on Nov 29, 2023. Reason: Presence of Particulate Matter: Silicone. Status: Ongoing.

Why it was recalled

Presence of Particulate Matter: Silicone

Product description

Midazolam in 0.8% Sodium Chloride Injection 100 mg/100 mL (1mg/mL), 100 mL Single-Dose Vial, 25 count carton, Ready to Use For Intravenous Infusion Only Preservative Free, Rx Only, Manufactured and Distributed by Exela Pharma Sciences, LLC, Lenoir, NC 28645, (Vial NDC 51754-2131-1; Carton NDC 51754-2131-4).

Lot numbers, UPCs & expiration codes

Lot # 10001088 exp 07/31/2024

Where it was sold

Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0117-2024
Classification
Class I
Status
Ongoing
Recall initiated
Oct 18, 2023
FDA report date
Nov 29, 2023
Quantity
23,425 vials
Recall type
Voluntary: Firm initiated
Recalling firm
Exela Pharma Sciences LLC

Original FDA data

Every field from FDA enforcement report D-0117-2024, exactly as published.

Show all FDA fields
City
Lenoir
State
NC
Status
Ongoing
Country
United States
Event ID
93265
Address
1245 Blowing Rock Blvd
Code information
Lot # 10001088 exp 07/31/2024
Postal code
28645-3618
Report date
Nov 29, 2023
Product type
Drugs
Recall number
D-0117-2024
Classification
Class I
Recalling firm
Exela Pharma Sciences LLC
Product quantity
23,425 vials
Reason for recall
Presence of Particulate Matter: Silicone
Voluntary / mandated
Voluntary: Firm initiated
Product description
Midazolam in 0.8% Sodium Chloride Injection 100 mg/100 mL (1mg/mL), 100 mL Single-Dose Vial, 25 count carton, Ready to Use For Intravenous Infusion Only Preservative Free, Rx Only, Manufactured and Distributed by Exela Pharma Sciences, LLC, Lenoir, NC 28645, (Vial NDC 51754-2131-1; Carton NDC 51754-2131-4).
Distribution pattern
Nationwide
Recall initiation date
Oct 18, 2023
Initial firm notification
Letter
Center classification date
Nov 22, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0117-2024, published Nov 29, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls